Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: An in vivo study in rats

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 7, 2006, Pages 305-311

  Zornoza, T ^a   Cano Cebrian M J ^a   Hipolito L ^a   Granero, L ^a   Polache, Ana ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Absorption; Acamprosate; Elimination; Flip flop model; Pharmacokinetics

Indexed keywords

ACAMPROSATE; MW 403;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG FECES LEVEL; DRUG URINE LEVEL; IN VIVO STUDY; JUGULAR VEIN; LIQUID SCINTILLATION COUNTING; MALE; NONHUMAN; QUANTITATIVE ANALYSIS; RANDOMIZATION; RAT; STOMACH INTUBATION;

ALCOHOL DETERRENTS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; MALE; RATS; RATS, WISTAR; TAURINE;

EID: 33750615549     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.513     Document Type: Article

References (23)

1. Zornoza T, Cano MJ, Polache A, Granero L. Pharmacology of acamprosate: an overview. CNS Drug Rev 2003; 9: 359-374.
2. Chabenat C, Chretien P, Daoust M, et al. Physicochemical, pharmacological and pharmacokinetic study of a new gabaergic compound, calcium acetylhomotaurinate. Methods Find Exp Clin Pharmacol 1988; 10: 311-317.
3. Lhuintre JP, Daoust M, Moore ND, et al. Ability of calcium bisacetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1985; 1: 1014-1016.
4. Lhuintre JP, Moore ND, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 1990; 25: 613-622.
5. Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 1996; 53: 673-680.
6. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 1996; 347: 1438-1442.
7. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001; 62: 42-48.
8. Soyka M, Preuss U, Schuetz C. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholics. Results from a non-blind, multicenter study. Drugs Res Dev 2002; 3: 1-12.
9. Scott LJ, Figgitt DP, Keam SJ, Waugh J. Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence. CNS Drugs 2005; 19: 445-464.
10. Fourtillan JB. Pharmacokinetics of acetylhomotaurine (AOTA) in young healthy volunteers subjects after single and multiple oral administrations of doses equal to 666 mg of calcium acetylhomotaurinate (AOTA-Ca). Lipha France (Data on file). AD 875H. 1990.
11. Dewland PM. A rising dose tolerance and pharmacokinetic study of calcium bis acetylhomotaurinate following single oral administration of a solution at four dose levels. Lipha France (Data on file). RD 298/ 17949.1991.
12. Saivin S, Hulot T, Chabac S, Potgieter A, Durbin P, Houin G. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998; 35: 331-345.
13. Zornoza T, Cano-Cebrián MJ, Nalda-Molina R, Guerri C, Granero L, Polache A. Assessment and modulation of acamprosate intestinal absorption: comparative studies using in situ, in vitro (Caco-2 cell monolayers) and in vivo models. Eur J Pharm Sci 2004; 22: 347-356.
14. Zornoza T, Guerri C, Polache A, Granero L. Disposition of acamprosate in the rat influence of probenecid. Biopharm Drug Dispos 2002; 23: 283-291.
15. Torres-Molina F, Peris JE, García-Carbonell MC, Aristorena JC, Granero L, Chesa-Jiménez J. Use of rats chronically cannulated in the jugular vein and the duodenum in pharmacokinetic studies. Arzneimittelforschung 1996; 46: 716-719.
16. Gibaldi M, Perrier D (eds). Pharmacokinetics, 2nd edn. Dekker: New York.
17. Akaike H. An information criterion (AIC). Mathem Sci 1986; 14: 5-9.
18. Wagner JG (ed.). Fundamentals of Clinical Pharmakokinetics. Drug Intelligence Publications: Illinois, 1979.
19. Notari RE (ed.). Biopharmaceutics and Clinical Pharmacokinetics, 4th edn. Marcel Dekker: New York, 1987.
20. Boxenbaum H. Pharmacokinetics tricks and traps: Flip-flop models. J Pharm Pharm Sci 1998; 1: 90-91.
21. Toutain PL, Bousquet-Mélou A. Plasma terminal half-life. J Vet Pharmacol Ther 2004, 27: 427-439.
22. Teo SK, Colburn WA, Tracewell WG, et al. Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet 2004; 43: 311-327.
23. Chen AS, Taguchi T, Okamoto H, et al. Pharmacokinetics of chitobiose and chitotriose administered intravenously or orally to rats. Biol Pharm Bull 2005; 28: 545-548.